Clinical Trials on Macular Edema Secondary to Retinal Vein Occlusion in Czechia

Total 40 results

Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)

Central Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)

Macular Edema | Branch Retinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Allergan

Completed

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Macular Edema | Retinal Vein Occlusion

France, United States, Canada, Taiwan, Australia, Austria, Czechia, Portugal, Germany, Israel, Philippines, Mexico, South Africa
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) (COMRADE-B)

Macular Edema | Visual Impairment | Branch Retinal Vein Occlusion

Germany, United Kingdom, Hungary, Poland, Czech Republic
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRYSTAL)

Central Retinal Vein Occlusion | Macular Edema

Greece, Hungary, Turkey, Australia, Austria, Netherlands, United Kingdom, Italy, Spain, Ireland, Portugal, Slovakia, Canada, Switzerland, Czech Republic, Poland, Denmark, Sweden
Kodiak Sciences Inc

Completed

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) (BEACON)

Macular Edema | Retinal Vein Occlusion

Spain, United States, Latvia, Israel, France, Italy, Hungary, Germany, Poland, Slovakia, Puerto Rico, Czechia
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan
University of Iceland
Medical University of Vienna; University Hospital, Basel, Switzerland; University... and other collaborators

Completed

Study of Retinal Oxygenation in Central Retinal Vein Occlusion

Retinal Vein Occlusion

Austria, Czechia, Denmark, Germany, Iceland, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (BRIGHTER)

Branch Retinal Vein Occlusion

Greece, Hungary, Australia, Spain, United Kingdom, Italy, Netherlands, Ireland, Portugal, France, Slovakia, Canada, Switzerland, Czech Republic, Poland, Denmark, Sweden
Allergan

Completed

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

Diabetic Macular Edema

Spain, South Africa, Canada, Czech Republic, Germany, Israel, Australia, Portugal, United States, Philippines
Abbott Products

Completed

Effect of Choline Fenofibrate (SLV348) on Macular Edema

Diabetic Macular Edema

Bulgaria, Czech Republic, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain, United Kingdom
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) (DME)

Diabetic Macular Edema

Japan, United States, Czechia, Germany, Hungary, India, Latvia, Poland, Russian Federation
Hoffmann-La Roche

Active, not recruiting

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Diabetic Macular Edema

United States, United Kingdom, Korea, Republic of, Argentina, Poland, Puerto Rico, Czechia, Spain, Canada
Hoffmann-La Roche

Recruiting

Vamikibart in Participants With Uveitic Macular Edema (Sandcat)

Uveitic Macular Edema

India, United States, Japan, Australia, Singapore, Turkey, Argentina, Czechia, Spain, France, Germany, Switzerland
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

Geographic Atrophy Secondary to Age-related Macular Degeneration

United States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)

Diabetic Macular Edema

Korea, Republic of, United States, United Kingdom, Brazil, China, Canada, Argentina, Australia, Denmark, France, Italy, Poland, Spain, Germany, Singapore, Czechia, Hong Kong, Portugal, Russian Federation, Taiwan, Hungary, Switzerland and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)

Diabetic Macular Edema

United States, Korea, Republic of, United Kingdom, Brazil, Japan, Canada, Argentina, Australia, Austria, Denmark, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Singapore, Czechia, Hong Kong, Israel, Portugal, Russian Federation and more
Bayer

Completed

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) (VIOLET)

Macular Edema

Spain, Canada, Switzerland, Portugal, Austria, Poland, Slovakia, United Kingdom, Germany, Hungary, Italy, France, Lithuania, Czechia
ThromboGenics

Completed

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Diabetic Retinopathy | Macular Edema

Czechia, Slovakia, Hungary
Novartis Pharmaceuticals

Completed

To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

Macular Edema (ME)

Russian Federation, Turkey, United Kingdom, Belgium, Australia, Hungary, Switzerland, Germany, Italy, Korea, Republic of, Israel, Spain, France, Latvia, Netherlands, Slovakia, Czech Republic, Singapore, Canada
Pfizer

Completed

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Macular Edema Associated With Diabetes Mellitus

United States, Colombia, Australia, Germany, Italy, South Africa, Greece, France, Austria, United Kingdom, Denmark, India, Portugal, Brazil, Canada, Czechia, Netherlands, Switzerland
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE)

Diabetic Macular Edema

Czechia, India, Russian Federation, Taiwan, Turkey, Lebanon, Denmark, Estonia, France, Germany, Hungary, Korea, Republic of, Latvia, Lithuania, Bulgaria, Norway, Belgium, Malaysia, Sweden, Slovakia, Singapore, Poland, Switzerland
Bayer

Completed

Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. (AQUA)

Macular Edema

Spain, Canada, Switzerland, Portugal, Austria, Poland, Slovakia, United Kingdom, France, Czechia, Germany, Hungary, Italy, Lithuania
Pfizer

Terminated

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

Macular Edema, Diabetic

United States, Israel, Germany, Hungary, Bulgaria, Czech Republic, Moldova, Republic of, Poland, Romania
Oxurion

Completed

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema (KALAHARI)

Diabetes Mellitus | Diabetic Retinopathy | Diabetic Macular Edema

United States, France, United Kingdom, Spain, Germany, Italy, Slovakia, Czechia
Hoffmann-La Roche

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Germany, Croatia, Japan, United Kingdom, Spain, United States, Italy, Switzerland, Canada, France, Australia, Singapore, Israel, Puerto Rico, United Arab Emirates, Bulgaria, Chile, Czechia
Kodiak Sciences Inc

Terminated

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLIMMER)

Diabetic Macular Edema

United States, Israel, France, Italy, Hungary, Poland, Puerto Rico, Czechia
Fovea Pharmaceuticals SA

Completed

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

Diabetic Macular Edema

United States, Australia, Belgium, Czech Republic, France, Germany, Israel, Italy, Poland, Spain
Bayer
Regeneron Pharmaceuticals

Completed

Intravitreal Aflibercept Injection in Vision Impairment Due to DME (VIVID-DME)

Diabetes Mellitus | Macular Edema

France, Japan, Australia, Austria, Poland, Czechia, Denmark, Germany, Hungary, Italy, Spain
Quark Pharmaceuticals

Completed

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) (MATISSE)

Diabetic Retinopathy | Diabetic Macular Edema | Choroidal Neovascularization

United States, Israel, United Kingdom, Belgium, Germany, Poland, Czech Republic
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus (RETAIN)

Diabetic Macular Edema

Belgium, United Kingdom, Netherlands, Ireland, Switzerland, Italy, Hungary, France, Spain, Portugal, Poland, Czech Republic, Greece
Regeneron Pharmaceuticals
Bayer

Active, not recruiting

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (PHOTON)

Type 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes Mellitus

United States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary
LEO Pharma

Completed

Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis

Deep Vein Thrombosis

Bulgaria, Croatia, Czechia, France, Germany, Poland, Romania, Serbia, Spain
Kips Bay Medical, Inc.

Unknown

The eMESH 1 Feasibility Study (eMESH 1)

Atherosclerosis of Autologous Vein Coronary Artery Bypass Graft(s)

United States, United Kingdom, Czech Republic, Netherlands, France, Italy, Switzerland
Cook Group Incorporated

Completed

Formula PTX Renal Stent Clinical Study

Renal Artery Stenosis

United Kingdom, Germany, Czechia, France
Bayer

Completed

Gadobutrol Enhanced MRA of the Renal Arteries (GRAMS)

Renal Artery Obstruction

Taiwan, United States, Korea, Republic of, France, Turkey, Switzerland, Austria, Poland, Brazil, Colombia, Germany, Czech Republic, Argentina
Medtronic

Recruiting

Product Surveillance Registry (PSR)

Coronary Artery Disease | Renal Insufficiency | Neurological Disorders | Intracranial Aneurysm | Surgical Procedures, Operative | Respiratory Therapy | Minimally Invasive Surgical Procedures | Cardiac Rhythm Disorders | Urological Disorders | Cardiovascular Disorders | Digestive Disorders | Mechanical Circulatory... and other conditions

China, France, Italy, United States, Spain, Australia, Belgium, Denmark, Germany, Greece, Hungary, Israel, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Portugal, Serbia, Sweden, Switzerland, United Kingdom, Argentina, Brazil and more

Clinical Trials on Macular Edema Secondary to Retinal Vein Occlusion in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations